DREAMM-15

TRIO-US GSK 224317 (DREAMM-15) A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed- refractory multiple myeloma